A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES

One hundred and twelve patients received hematopoietic stent cell transplantation (HSCT), including 91patients with acute leukemia, 12 patients with chronic nyeloid leukemia, 7 patients with lymphoma and 2patients with myeloma and neuroblastoma respectively.Among them, 14 patients were treated with unpurged autologous bone marrow transplantation (ABMT), 25patients with purged autologous bone marrow transplantation (PABMT), 40 patients with autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT), 24 patients with allogencic bone marrow transplautation (Allo-BAT), 9 patients with fetal liver hematopoietic stem cell transplantation (FLHSCT). The three year disease free survival (DFS) rates in these five groups were 68.3%, 67.5%, 69.54%, 57.12% and 33.33%respectively. The relapse rates were 30.76%, 26.80%,20.8%, 13% and 62.5% respectively. In contrast, in the conventional chemotherapy group, the three year DFS rate and relapse rate were 7.385 and 76.4% respectively.These results indicated that the APBHSCT group had a quicker hematopoietic reconstitution with less complication of infection. All of these five transplantation groups had much higher three years disease free survival rates than that of the conventional chemotherapy group.